Medical Marijuana (MMJ)

This recently published study examined the effects of personalized coaching on the use of medical cannabis for chronic pain.

In this research overview, Ruth Fisher, PhD, explores how cannabis has shown promise in helping individuals reduce opioid use, potentially decreasing overdose deaths. Though its impact on chronic pain and opioid reduction remains evident, limitations exist and flaws in methodologies in ecological studies complicate conclusions.

The partnership aims to support research, education, and patient access, aligning with both companies’ missions.

The internship will provide hands-on experience in medical cannabis cultivation in the country’s expanding medical cannabis market.

In response to the recent announcement that the hearing concerning cannabis rescheduling had been delayed, Americans for Safe Access held a webinar discussing the impacts medical cannabis.

Kentucky launched its medical cannabis program on January 1, 2025, allowing patients with qualifying conditions to apply for ID cards.

It’s that time of year again—the Cannabis Science and Technology (CST) top 10 articles from the previous year. CST published a wide variety of content throughout 2024. Here is just a small snippet of some of the top articles that our readers enjoyed. See if any of your favorites made the list!

Germany’s Cannabis Act (CanG) is beginning to transform the country's medical cannabis market, with potential opportunities to expand telemedicine, improve physician training, and enhancing accessibility in this rapidly growing industry.

The patient-centered organization announced its 2025 plans for medical cannabis at the national level.

This month’s webinar covered recent studies on cannabis use during pregnancy, CBD and anxiety, cannabis tea, and more.

This month’s webinar covered research on cannabis studied as a treatment for rheumatic disorders, menstrual symptoms, eczema, and more.

MM411’s president and co-founder, Chris DeVol, discusses challenges and trends in global cannabis education, plus upcoming initiatives of the company.

MM411’s president and co-founder, Chris DeVol, discusses the evolution of the company, their most popular cannabis education courses, and their partnership with Cannabis Science and Technology.

Overall, the survey revealed that people with chronic pain supported policies expanding medical cannabis access more than physicians.

A ruling is expected this week regarding the lawsuit challenging the validity of signatures collected for two medical cannabis measures.

As discussions about the federal scheduling of cannabis continue, efforts by medical cannabis advocates are intensifying. One such advocate is Americans for Safe Access (ASA), a nonprofit organization founded by patients for patients. Since 2002, ASA has been championing the rights of medical cannabis patients and has recently launched new campaigns and strategies to refocus attention on patient needs. In this interview, Steph Sherer, founder and president of ASA, reflects on past successes in medical cannabis advocacy, shares her perspective on recent cannabis and hemp policymaking, and outlines the next steps for advancing a unified medical cannabis message on Capitol Hill—a message that could bring about the changes patients have long awaited.

This month’s Healer webinar provided a deep dive into several studies on cannabis for various conditions.

California’s bill creating new restrictions on intoxicating hemp products has prompted responses citing negative impacts on patients and businesses.

Americans for Safe Access, a medical cannabis patient advocacy organization, held a briefing on the final day of the comment period for the proposed rulemaking on cannabis.

The Senate’s latest attempt at legal medical cannabis access for patients was added to a bill on hemp regulations.

This month’s Healer webinar discussed several studies on cannabis and symptoms of dementia and cognitive decline.

Nebraska advocates are a few weeks away from knowing if two medical cannabis measures have enough signatures to qualify to appear on the 2024 ballot.

The new law eliminates the 37% excise tax for medical cannabis cardholders for certain products.

This webinar from MM411 explored the far-ranging studies of Dr. Raphael Mechoulam and Dr. Ethan Russo on the science and medicine of cannabis and other plants.

The US Attorney General has initiated the process to reclassify cannabis from a Schedule I to a less-restrictive Schedule III substance.